Replies to post #248020 on Avid Bioservices Inc (CDMO)

[horselover45]

I guess that you don't realize why some people are here.
Def not to talk about success of Peregrine and Bavituximab.

Just an oldtimer's opinion.
Andy

[Couch]

The institutions represented by NCCN are some of the most prestigious and advanced global bodies that partner on development of medicines, run trials and treat patients.

I'm very confused reading some posts that look at this as an act of desperation or hedging of bets. Getting a product to be accepted into NCCN for evaluation and broad testing is a privilege - not an entitlement.

So - yes. This provides both an insurance policy for high integrity and access to the basket of modern meds that various pharmas and research institutions have deployed or are in the process of evaluating. It's the best federated model one can get where the best expertise in drug development and testing comes together with the broadest range of combo candidates to see what can be brought to bear.

It's all pointing to the strategy of filing for Lung with Bavi/Doce closely followed by multiple filing for multiple indications through the various collaborations - should they produce the results we hope.

Thanks MH. I had no doubt that this collaboration with NCCN wasn't born out of desperation but actually nice to hear it from one with an inside perspective. To me this collaboration highlights additional proof that PPHM believes it has what it says it has - astronomical value in Bavi. It comes down to your last statement - "should they produce the results we hope."

In other words, should Bavi prove effective in helping other drugs fight cancer this collaboration with NCCN is only going to help Peregrine do so more effectively and quickly. Seems to me time and money well spent.

My best,
Couch

[md1225]

Thank you mass! If you don't mind I will copy and email this post to many whom asked me questions about this collaboration on SA. My feelings exactly, bavituximab will be everything Avastin wanted to be.... but never achieved.

[biopharm]

The institutions represented by NCCN are some of the most prestigious and advanced global bodies that partner on development of medicines, run trials and treat patients.

I'm very confused reading some posts that look at this as an act of desperation or hedging of bets. Getting a product to be accepted into NCCN for evaluation and broad testing is a privilege - not an entitlement. The people who do the work are scientists, the best in the world, who do not take their work lightly and absolutely do not see themselves as assembly line workers just pushing the next product through its paces while collecting a salary. They spend their lives looking for cures and ways to help fight disease. They are never the dumpling grounds for a company's molecule desperately looking for a problem to solve...

So - yes. This provides both an insurance policy for high integrity and access to the basket of modern meds that various pharmas and research institutions have deployed or are in the process of evaluating. It's the best federated model one can get where the best expertise in drug development and testing comes together with the broadest range of combo candidates to see what can be brought to bear.

It's all pointing to the strategy of filing for Lung with Bavi/Doce closely followed by multiple filing for multiple indications through the various collaborations - should they produce the results we hope.

I agree 100% and I'd also find trouble finding one other small biotech that has took this route "before" partnering ?

Some can look at it two ways.... but there are many paths on why a small biotech ends up partnering with a Big Pharma, though it mostly is something that mostly all are "FORCED" into because of the lack of funds and knowing eventually, they are sincerely forced into some breadcrumb (borrowing CP's term..) deal, and many don't realize they are even being fed breadcrumbs until they see years later that their molecule or drug..etc is part of a Billion dollar mafia empire of Big Pharma.

Peregrine knows all this early on and they are thankfully, doing things that are unheard of ever before to take a road that is less traveled or should say never traveled before for a small biotech.

I like how you mentioned "insurance.." MH, because think of what Big Pharma knows and know imagine them just knowing that PS Targeting is not even in the hands of MSK/AZ but soon the game is wide open as it is left in the hands of hundreds of NCCN researchers that want to make a name for themselves as well. Who knows what is published one day from this collaboration and would one Big Pharma risk not taking control of the situation now and early on before one day they wake up to see PPHM rising and rising and all of a sudden having the leverage of just possibly buying out a few smaller size pharmas and they (a Gilead) possibly, losing out and coming so close to having PS Targeting under their roof.

[itsabouttime]

MH Bottom line. Clear strategy.


It's all pointing to the strategy of filing for Lung with Bavi/Doce closely followed by multiple filing for multiple indications through the various collaborations - should they produce the results we hope.

[jakedogman1]

MH, great stuff as usual.... how far down the fda (potential)approval path does bavi (or other drugs) need to be for NCNN players to even consider spending time on them? What is the catalyst for them to consider a bavi? What level of data (preclin or better?) and what level of wow factor? If bavi was a new molecule with minimum testing to date would NCNN consider looking at it? Given the thousands and thousands of molecules out there, what drives this bus?